DBV

DBV Technologies Files 2026 Half-Year Report: Progress on VIASKIN Food Allergy Treatment

by

DBV Technologies, a clinical-stage biopharmaceutical company focused on the treatment of food allergies, has officially filed its 2026 half-year financial report with the Autorité des Marchés Financiers (AMF), France’s financial markets regulator. This regulatory disclosure, published in accordance with transparency requirements for publicly traded companies, provides an updated look at the company’s operational progress and … Read more

DBV Technologies Unveils Promising Data for Peanut Allergy Treatment

by

DBV Technologies, a clinical-stage biopharmaceutical company, is currently advancing a pipeline of investigational treatments for food allergies, centered on its proprietary epicutaneous immunotherapy (EPIT) technology. The firm, which was established by pediatricians, focuses on the development of the VIASKIN® patch, a device designed to re-educate the immune system by delivering minimal amounts of antigen through … Read more